Octapharma AG - Company Profile
Powered by 
All the sales intelligence you need on Octapharma AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Octapharma AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Octapharma AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Octapharma AG (Octapharma) is a global healthcare company primarily engaged in the development and manufacturing of high-quality human protein products. The company focuses on three therapeutic areas: haematology, immunotherapy, and critical care.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D activities focus on developing VHH antibodies, also known as nanobodies, derived from camelid blood. These small, highly specific antibodies have the potential to transform treatment strategies across multiple therapeutic fields, including critical care, haematology, and immunotherapy. The company is investing in this rapidly expanding area of research, aiming to address unmet medical needs with innovative biologics. Additionally, Octapharma is working on improving immunoglobulin (IgG) yields from plasma-derived products, with a strategic focus on data collection and analytics to enhance manufacturing processes and prevent IgG losses. The R&D units of Octapharma AG include the Recombinant R&D division and the R&D Molecular Design Group. The Recombinant R&D division is focused on pioneering innovative biologics using VHH antibody technology, and the R&D Molecular Design Group is responsible for lead discovery and refinement of VHH antibodies. The Plasma R&D unit focuses on increasing IgG yields and developing new plasma-derived products. The Product & Process Science division is involved in yield improvement projects for existing products. In FY2024, the company spent EUR107.8 million on its R&D activities, which as a percentage of revenue stood at 3.1% and grew 16.5% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer